EIT Pharma Highlights New Lonafarnib Analyses at EASL Congress 2026
EIT Pharma presented new analyses from the lonafarnib development program for Chronic Hepatitis Delta (CHD) at EASL Congress 2026 in Barcelona, Spain, held May 27–30, 2026. Due to the high unmet medical need in CHD, EIT Pharma resurrected the development of lonafarnib as the only late-stage oral option in late-stage development.